AR-42

別名：HDAC-42

製品コード：S2244 純度：99.03%

AR-42（HDAC-42）は、HDAC阻害剤であり、IC50は30 nMです。フェーズ1。

CAS No. 935881-37-1

サイズ	価格(税別)	在庫状況
2mg	JPY 22000	国内在庫あり
5mg	JPY 37000	国内在庫あり

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

文献中Selleckの製品使用例（30）

カスタマーフィードバック6例

製品安全説明書

現在のバッチを見る：純度： 99.03%

99.03

AR-42関連製品

関連ターゲット	HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2	もっと見る
関連製品	Entinostat (MS-275) Trichostatin A (TSA) Mocetinostat (MGCD0103) RGFP966 Tubastatin A Ricolinostat (ACY-1215) Quisinostat (JNJ-26481585) Dihydrochloride PCI-34051 MC1568 Tubastatin A Hydrochloride Tacedinaline (CI994) LMK-235 Fimepinostat (CUDC-907) Tubacin Sodium butyrate ITF-2357 (Givinostat) Hydrochloride Monohydrate TMP269 Tucidinostat (Chidamide) (-)-Parthenolide CAY10603 (BML-281) 4-PBA (4-Phenylbutyric acid) Santacruzamate A (CAY10683) Abexinostat (PCI-24781) Pracinostat (SB939) TMP195 CUDC-101 RG2833 (RGFP109) Dacinostat (LAQ824) Tasquinimod Droxinostat Domatinostat (4SC-202) Scriptaid Nexturastat A M344 (D 237) Resminostat Quisinostat Citarinostat (ACY-241) ITSA-1 (ITSA1) BG45 SIS17 Tubastatin A TFA WT161 ACY-738 HPOB TC-H 106 Sinapinic Acid UF010 ACY-775 TH34 Raddeanin A Tinostamustine(EDO-S101) Pyroxamide (NSC 696085) BRD-6929 BML-210 (CAY10433) SR-4370 HDAC5 Antibody (Rabbit mAb) [A22G14]	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Highly Selective Inhibitor Library	もっと見る

シグナル伝達経路

HDACシグナル伝達経路

HDAC阻害剤の選択性比較

生物活性

製品説明

AR-42（HDAC-42）は、HDAC阻害剤であり、IC50は30 nMです。フェーズ1。

特性

Greater potency relative to SAHA.

Targets

HDAC
(Cell-free assay)

30 nM

In Vitro
In vitro	AR-42 treatment induces histone hyperacetylation and p21^WAF/CIP1 overexpression, and inhibits the growth of DU-145 cells with IC50 of 0.11 μM. This compound is potent in suppressing the proliferation of U87MG and PC-3 cells, in part, because of its ability to down-regulate Akt signaling. It inhibits the growth of PC-3 and LNCaP cells with IC50 of 0.48 μM and 0.3 μM, respectively. Compared to SAHA, this chemical exhibits distinctly superior apoptogenic potency, and causes markedly greater decreases in phospho-Akt, Bcl-xL, and survivin in PC-3 cells. This compound treatment induces growth inhibition, cell- cycle arrest, apoptosis, and activation of caspases-3/7 in malignant mast cell lines. It induces down-regulation of Kit via inhibition of Kit transcription, disassociation between Kit and heat shock protein 90 (HSP90), and up-regulation of HSP70. This treatment down-regulates the expression of p-Akt, total Akt, phosphorylated STAT3/5 (pSTAT3/5), and total STAT3/5. It potently inhibits the growth of JeKo-1, Raji, and 697 cells with IC50 of <0.61 μM. This compound also sensitizes CLL cells to TNF-Related Apoptosis Inducing Ligand (TRAIL), potentially through reduction of c-FLIP. This treatment also induces autophagy through downregulation of Akt/mTOR signaling and inducing ER stress in hepatocellular carcinoma (HCC) cells.
Kinase Assay	In vitro HDAC assay
Kinase Assay	HDAC activity is analyzed by using an HDAC assay kit. This assay is based on the ability of DU-145 nuclear extract, which is rich in HDAC activity, to mediate the deacetylation of the biotinylated [³H]-acetyl histone H4 peptide that is bound to streptavidin agarose beads. The release of [³H]-acetate into the supernatant is measured to calculate the HDAC activity. Sodium butyrate (0.25-1 mM) is used as a positive control.
細胞実験	細胞株	DU-145
	濃度	Dissolved in DMSO, final concentrations ~2.5 μM
	反応時間	96 hours
	実験の流れ	Cells are exposed to varous concentrations of AR-42 for 96 hours. The medium is removed and replaced by 150 μL of 0.5 mg/mL of MTT in RPMI 1640 medium, and the cells are incubated in the CO₂ incubator at 37 °C for 2 hours. Supernatants are removed from the wells, and the reduced MTT dye is solubilized with 200 μL/well of DMSO. Absorbance is determined on a plate reader at 570 nm.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	Notch1 / NICD / Nestin / Zeb-1 / BMI-1 p-Kit / Kit Act-H3 / Act-H3 / Act-tubulin Cyclin D1 / p21 / p16 / Cyclin A / Cyclin B1 gp130 / p-STAT3 / STAT3 / p-AKT / AKT / p-MEK / MEK		26625202
	Growth inhibition assay	Cell viability		26993777

In Vivo
In Vivo	The growth of PC-3 tumor xenografts is suppressed by 52% and 67% after treatment with AR-42 at 25 mg/kg and 50 mg/kg, respectively, whereas SAHA at 50 mg/kg suppresses growth by 31%. In contrast to mice treated with SAHA, intratumoral levels of phospho-Akt and Bcl-xL are markedly reduced in this compound treated mice. In the transgenic adenocarcinoma of the mouse prostate (TRAMP) model, administration of this chemical not only decreases the severity of prostatic intraepithelial neoplasia (PIN) and completely prevents its progression to poorly differentiated carcinoma, but also shifts tumorigenesis to a more differentiated phenotype, suppressing absolute and relative urogenital tract weights by 86% and 85%, respectively. This agent significantly reduces leukocyte counts, and prolongs survival in three separate mouse models of B-cell malignancy without evidence of toxicity.
動物実験	動物モデル	Intact male NCr athymic nude mice inoculated s.c. with PC-3 cells
	投与量	~50 mg/kg/day
	投与経路	Orally

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2021-06-15)
NCT02569320	COMPLETED	Recurrent Plasma Cell Myeloma	Ohio State University Comprehensive Cancer Center	2016-05-20	PHASE1
NCT02282917	TERMINATED	Vestibular Schwannoma; Meningioma; Acoustic Neuroma; Neurofibromatosis Type 2	Massachusetts Eye and Ear Infirmary	2015-12	EARLY_PHASE1
NCT01129193	COMPLETED	Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Prolymphocytic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia	Amir Mortazavi	2010-05-04	PHASE1
NCT02795819	TERMINATED	Renal Cell Carcinoma; Soft Tissue Sarcoma; Metastatic Disease	Virginia Commonwealth University	2016-07-08	PHASE1
NCT02795819	Terminated	Renal Cell Carcinoma\|Soft Tissue Sarcoma\|Metastatic Disease	Virginia Commonwealth University\|National Cancer Institute (NCI)	2016-07-08	Phase 1
NCT02282917	Terminated	Vestibular Schwannoma\|Meningioma\|Acoustic Neuroma\|Neurofibromatosis Type 2	Massachusetts Eye and Ear Infirmary\|Johns Hopkins University\|Mayo Clinic\|Stanford University\|Ohio State University\|Nationwide Children''s Hospital	2015-12	Early Phase 1

参考
https://pubmed.ncbi.nlm.nih.gov/16107152/ https://pubmed.ncbi.nlm.nih.gov/16186112/ https://pubmed.ncbi.nlm.nih.gov/16951239/ https://pubmed.ncbi.nlm.nih.gov/17545612/ https://pubmed.ncbi.nlm.nih.gov/18483287/ https://pubmed.ncbi.nlm.nih.gov/20233974/ https://pubmed.ncbi.nlm.nih.gov/20532179/ https://pubmed.ncbi.nlm.nih.gov/20962572/ + 展開

参考

https://pubmed.ncbi.nlm.nih.gov/16107152/
https://pubmed.ncbi.nlm.nih.gov/16186112/
https://pubmed.ncbi.nlm.nih.gov/16951239/

https://pubmed.ncbi.nlm.nih.gov/17545612/
https://pubmed.ncbi.nlm.nih.gov/18483287/
https://pubmed.ncbi.nlm.nih.gov/20233974/
https://pubmed.ncbi.nlm.nih.gov/20532179/
https://pubmed.ncbi.nlm.nih.gov/20962572/

+ 展開

化学情報

分子量	312.36	化学式	C₁₈H₂₀N₂O₃
CAS No.	935881-37-1	SDF	Download AR-42 SDFをダウンロードする
Smiles	CC(C)C(C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

DMSO : 63 mg/mL ( (201.69 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 63 mg/mL

Water : Insoluble

モル濃度計算器

in vivo Batch: Add solvents to the product individually and in order.				投与溶液組成計算機
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	0.5% methylcellulose 1 0.2% Tween 80 この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	10.000mg/ml (32.01mM)	Taking the 1 mL working solution as an example, take 10 mg of this product, add it to 1 ml of 0.5% methylcellulose+0.2% Tween 80 clear solution, and mix evenly to make it a uniform suspension. The mixed solution should be used immediately for optimal results.

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):